Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018025184
pages 17-62

The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity

Jasper Rip
Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands
Esmee K. Van Der Ploeg
Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands
Rudi W. Hendriks
Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands
Odilia B. J. Corneth
Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands

RESUMO

Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the molecule affected in X-linked agammaglobulinemia (XLA) patients, who almost completely lack peripheral B cells and serum immunoglobulins. BTK is crucial for B cell development and various B cell functions, including cytokine and natural antibody production. Importantly, it is also expressed in numerous other cells, including monocytes, macrophages, granulocytes, dendritic cells, and osteoclasts. A few rare cases of autoimmune disease in XLA patients have been described. Interestingly, increased BTK protein expression in patients with systemic autoimmune disease appears to be correlated with autoantibody production. In addition, BTK may promote autoimmunity as an important driver of an imbalance in B-T cell interaction. Because of this overwhelming evidence of a pathogenic role of BTK in autoimmunity, several clinical trials in rheumatoid arthritis and systemic lupus erythematosus patients with BTK inhibitors are currently running. Here, we review BTK function in different signaling pathways and in different cell lineages, focusing on the growing body of literature indicating a critical role for BTK in autoimmunity. We also discuss BTK and the promising results of BTK inhibition in animal models of autoimmune disease.


Articles with similar content:

Activation of Mammalian Toll-like Receptors by Endogenous Agonists
Critical Reviews™ in Immunology, Vol.23, 2003, issue 1-2
Gregory J. Brunn, Jeffrey L. Platt, Geoffrey B. Johnson
Functions of Granulocyte-Macrophage Colony-Stimulating Factor
Critical Reviews™ in Immunology, Vol.25, 2005, issue 5
Andrew D. Cook, John A. Hamilton, Andrew J. Fleetwood
Tyrosine Phosphorylation in Immune Cells: Direct and Indirect Effects on Toll-Like Receptor-Induced Proinflammatory Cytokine Production
Critical Reviews™ in Immunology, Vol.29, 2009, issue 4
Pauline Johnson, Jennifer L. Cross
Functions of CD40 and Its Ligand, gp39 (CD40L)
Critical Reviews™ in Immunology, Vol.16, 1996, issue 1
Jon D. Laman, Randolph J. Noelle, Eric Claassen
Functions of CD40 and Its Ligand, gp39 (CD40L)
Critical Reviews™ in Immunology, Vol.37, 2017, issue 2-6
Jon D. Laman, Randolph J. Noelle, Eric Claassen